Gene Therapy

XLRP often leads to blindness by middle age with no treatment options currently available

Investigators say the discovery highlights the importance of genetic consultation

Simply slowing disease progression is no longer enough

Promising innovations are not one-size-fits-all

The tissue serves as a testing ground for outpatient ocular therapies

The opportunities and challenges presented by CRISPR manipulation

The Phase 2/3 VISTA trial for AGTC-501 in XLRP is expected to begin in in the first half of 2024

How this treatment paradigm could change ocular cell therapy

Data show transfection in both eyes despite unilateral injection

Infrastructure across Europe needs a major overhaul to optimise education and patient access in groundbreaking treatments

Bilateral distribution of the transgene seen with unilateral injection

The patent is also being prosecuted in the European Union and around the globe

For retinal specialists grappling with diseases once thought “untreatable,” gene therapies present a wide range of viable options

VG901 is a gene therapy for CNGA1-associated RP.

The London-based company will use regenerative medicine to fight ocular disease.

Hundreds of previously-unknown genes could be vital for early detection and treatment.

Ground-breaking treatment for bullous keratopathy approved in Japan

EMBL-EBI researchers use UK Biobank data to uncover new information about rare diseases of the eye.

A look at what’s in the therapeutic delivery pipeline for these disorders.

Recent research suggests the need for routine HSV-1 and VZV PCR testing in all explanted corneas regardless of clinical suspicion to detect, treat, and prevent possible recurrence of herpes infection in corneal grafts and support graft survival.

A recent survey of retinal clinic patients reveals a lack of awareness of the risks and safety issues associated with stem cell therapies.

Inflammation is par for the course in ocular gene therapy; preventing it should be the goal because once it develops, treatment can be difficult.

An end-of-week review of what happened in ophthalmology from 29 October to 3 November 2022.

Clinicians need to investigate patients’ history, family history, visual behaviours and general health in order to promptly and accurately refer paediatric cases to ocular genetics clinics.

Companies are exploring light-sensitive proteins method in patients with advanced disease.

According to one study, when genetic testing is coupled with advanced imaging, the chances of identifying keratoconus early are greater.

A synopsis of the findings presented at EURETINA 2022 for ophthalmologists and retina specialists.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

Recent reports of retinal atrophy have raised concerns on potential long-term safety.

The findings of this study may have revealed the crucial role of gene fragments in retinal development and vision.